There is usually a big disparity between investors and entrepreneurs regarding the valuation of an early-stage biotech company. How to determine what a company is actually worth? How do funds price the assets? What are the biases from each side? What are the points of negotiation?

Speakers
Ivan Burkov - INKEF Capital
Arnaud Autret - M Ventures
Eliott Harfouche - Nodes Advisors
Robert Tansley - Cambridge Innovation Capital
Sharon Cunningham - Shorla Pharma

Continue your tour